Dr. Sven Michel is the Head of Bioinformatics at Secarna Pharmaceuticals, specializing in next-generation antisense oligonucleotide (ASO) therapies. He leads the advancement of the companys proprietary bioinformatics platform and holds a Dr. rer. nat. from Hannover Medical School and a diploma from the Technical University of Munich.
He is a key inventor on patents related to antisense oligonucleotides for tumor treatment and has presented his research on ASO activity and targetability at international conferences.
Sven Michel
Head of Bioinformatics at Secarna Pharmaceuticals
Greater Munich Metropolitan Area, Germany
Overview
Topics They Care About
ASO Drug Discovery
He leads the bioinformatics platform at Secarna specifically designed for identifying and developing antisense oligonucleotide (ASO) therapies.
Bioinformatics Platforms
His work involves the ongoing optimization and use of Secarna's proprietary Oligofyer™ bioinformatics system for drug discovery.
RNA Therapeutics
His research and publications focus on the development of LNA-modified ASOs, a cutting-edge area in RNA-based medicine.
Media Appearances
Sven has no verified media appearances
Work History
2-2022
Head of Bioinformatics at Secarna Pharmaceuticals
12-2015
Scientist Bioinformatics at Secarna Pharmaceuticals
4-2014 - 12-2015
Bioinformatiker at DIS AG
Education
Dr. rer. nat. from Medizinische Hochschule Hannover
Dipl. Bioinf. from Technische Universität München / Ludwig-Maximilians Universität München
More Information
Social Presence :
Prographics :
Exp : 11
Location : Greater Munich Metropolitan Area, Germany
Job Level : Mid-senior
Designation : Head of Bioinformatics at Secarna Pharmaceuticals
